Delamanid, a new 6-nitro-2,3-dihydroimidazo[2,1-b]oxazole for the management of tuberculosis resistant to at least isoniazid and rifampicin

Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824

(2012) Andreas H. Diacon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance

(2012) A. H. Diacon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

(2012) Vija Skripconoka et al.   EUROPEAN RESPIRATORY JOURNAL

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial

(2012) Andreas H Diacon et al.   LANCET

Delamanid for Multidrug-Resistant Pulmonary Tuberculosis

(2012) Maria Tarcela Gler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients

(2011) A. H. Diacon et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients

(2010) A. H. Diacon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis

(2008) R. Rustomjee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY